REQUEST A DEMO
Total
USD $0.00
Search more companies

Lumosa Therapeutics Co., Ltd. (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Lumosa Therapeutics Co., Ltd. Profile Updated: July 05, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

Lumosa Therapeutics Co., Ltd.. specializes in the research and development and production of innovative drugs or medicine. The company was founded in 2000 and is located in Taipei City.

Headquarters
4F, No. 3-2, Park St., Nangang Dist
Taipei City; Taipei City;

Contact Details: Purchase the Lumosa Therapeutics Co., Ltd. report to view the information.

Website: http://www.lumosa.com.tw

Basic Information
Total Employees:
Purchase the Lumosa Therapeutics Co., Ltd. report to view the information.
Outstanding Shares:
Purchase the Lumosa Therapeutics Co., Ltd. report to view the information.
Financial Auditors:
Purchase the Lumosa Therapeutics Co., Ltd. report to view the information.
Incorporation Date:
November 13, 2000
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Manager
Ownership Details
Purchase this report to view the information.
33.15%
Purchase this report to view the information.
1.07%
Purchase this report to view the information.
0.29%
Purchase this report to view the information.
Purchase this report to view the information.
Subsidiaries
Lumosa Theapeutics Co., Ltd. (United Kingdom)
100%
顥晟生醫股份有限公司
60%
Company Performance
Financial values in the chart are available after Lumosa Therapeutics Co., Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
-49.68%
Total operating revenue
-48.5%
Operating profit (EBIT)
-98.05%
EBITDA
17.31%
Net Profit (Loss) for the Period
-116.57%
Total assets
-20.6%
Total equity
-23.82%
Operating Profit Margin (ROS)
-1146.3%
Net Profit Margin
-1123.99%
Return on Equity (ROE)
-15.62%
Debt to Equity Ratio
0.72%
Quick Ratio
-2.12%
Cash Ratio
-0.65%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?